Recognizing When Acute Migraine Patients Need More Than Monotherapy

Key Takeaways:

• 44 percent of Migraine In America respondents reported using an oral triptan in the past but not currently — a pattern consistent with peer-reviewed evidence of low long-term triptan retention and frequent switching among real-world users.
• Identifying these patients depends less on attack frequency than on the efficacy of acute response: completeness of pain resolution at 2 hours, sustained pain-free response through 24 hours, presence of associated symptoms, and tolerability.
• When combination acute therapy (NSAID + triptan) is considered, benefit-risk evaluation is part of standard decision-making, including the NSAID-class boxed warning content for cardiovascular thrombotic and gastrointestinal events.

Acute migraine treatment has long defaulted to triptan or NSAID monotherapy. A substantial number of patients do well on a single agent. A meaningful population does not – and that group is not always identified in routine clinical encounters.

The question is not only how many migraine days a patient has; it is whether the acute regimen they are using is doing the work it needs to do, attack by attack.

Identifying inadequate response to monotherapy

In the Migraine In America 2025 survey, 44 percent of 3,511 community members reported having used an oral triptan in the past but discontinued. Peer-reviewed real-world evidence supports the pattern: A 2021 systematic literature review of triptan users documented low 2-year retention rates, with high rates of switching to non-specific acute medications, and 18 percent of patients in the United States switching to opioids at first refill.^1,2

The International Headache Society's 2024 acute treatment guidelines define pain freedom at 2 hours as the primary measure of acute treatment efficacy, with sustained pain freedom through 24 hours and absence of the most bothersome migraine-associated symptom at 2 hours as secondary endpoints.³

In clinical practice, these align with distinct response gaps that monotherapy can fail to close:

• Incomplete pain resolution at 2 hours
• Relapse – return of headache of any severity within 48 hours among patients who were pain-free at 2 hours, with a 24-hour interval considered for agents with a short half-life
• Persistent photophobia, phonophobia, or nausea past 2 hours
• Tolerability-limited use (chest tightness, paresthesias, or fatigue)

Patients often describe these as "the medication works sometimes" or "I get relief, but it comes back." They are not equivalent presentations. Identifying them clinically requires direct questions about completeness and durability of acute response – not just attack frequency.¹

The case for combination acute therapy

Combination acute therapy – pairing an NSAID with a triptan – has the longest-standing clinical precedent of any acute migraine escalation strategy. 2007 trials of a fixed-dose sumatriptan plus naproxen sodium tablet (n = 1,461 and 1,495) demonstrated superior 2-hour headache relief versus placebo (65 percent and 57 percent versus 28 percent and 29 percent; P < 0.001) and superior 2- to 24-hour sustained pain-free response versus each monotherapy and placebo.⁵

Professional society guidance reinforces the class concept beyond adult acute care: The AAN/AHS pediatric acute migraine guideline recognizes the sumatriptan-naproxen combination as an established acute therapy class concept in adolescents, supporting professional society endorsement of the combination across age groups.⁶

More recently, Phase 3 evidence from a meloxicam-rizatriptan combination tablet (n = 1,594) demonstrated 2-hour pain freedom of 20 percent versus placebo 7 percent (P < .001 vs placebo) and 24-hour sustained pain freedom of 16.1 percent versus rizatriptan alone 11.2 percent (P = .038), meloxicam alone 9 percent (P = .001), and placebo 5 percent (P < .001).⁴

The mechanistic rationale is direct: Triptans (5-HT1B/1D receptor agonists) act at both peripheral trigeminal nerve terminals and central trigeminovascular sites, reducing neuropeptide release and trigeminal neuronal activation. NSAIDs act peripherally via cyclooxygenase inhibition, attenuating the prostaglandin-mediated meningeal inflammation that contributes to central sensitization.^5,7

The targets are complementary, not redundant. A 2026 expert opinion paper concludes that triptans or triptan-NSAID combinations should be prescribed for acute migraine attacks when NSAIDs alone have proven insufficiently effective.7

Benefit-risk in patient selection

Where combination acute therapy is considered, the boxed warning content for the NSAID component shapes who is a candidate – not whether escalation is warranted. The NSAID class carries cardiovascular thrombotic risk (including myocardial infarction and stroke. Risk may begin early in treatment and increase with duration of use) and gastrointestinal risk (bleeding, ulceration, and perforation; events can occur without warning symptoms and are higher in elderly patients and those with prior peptic ulcer disease or GI bleeding).⁴

These are class warnings, not novel signals. They define candidate selection:^4,8

• Higher cardiovascular risk – established CV disease, multiple CV risk factors, advanced age – warrants careful evaluation
• Higher gastrointestinal risk – prior peptic ulcer disease, history of GI bleeding, concomitant anticoagulants or corticosteroids
• Renal, hepatic, blood pressure, and hydration status – additional NSAID tolerability factors

For patients where NSAID exposure is contraindicated, alternatives within the acute treatment landscape remain available, including small-molecule CGRP receptor antagonists (gepants), 5-HT1F receptor agonists, dopamine antagonists, antiemetics, and neuromodulatory devices.^3,9

The clinical decision is rarely "combination or monotherapy"; it is "which acute therapy fits this patient's response gap and risk profile."

What this means in practice

Three concrete shifts. When a patient on a triptan reports inconsistent or partial response, probe specifically: How complete is the relief at 2 hours? Does the pain return within 24 hours? Are nausea or sensitivity symptoms still present at 4 hours? Frequency questions alone miss this picture.³

A validated resource clinicians can use to "probe" is the mTOQ, or Migraine Treatment Optimization Questionnaire, which assesses whether a patient’s acute migraine treatment is adequately optimized.¹⁰

When escalating, frame the conversation around the response gap being addressed – not around adding "another medication." The clinical logic is targeted: complementary peripheral and central mechanisms for an attack profile where one mechanism alone is not enough.^5,7

Build the benefit-risk conversation into the same visit. Patient-level cardiovascular and gastrointestinal risk assessment is part of the prescribing decision, not a follow-up step.^4,8

The 44 percent of community-surveyed patients who have discontinued an oral triptan are not all candidates for combination acute therapy. But many are signaling, in the most direct way available, that the current acute regimen is not the right one. Identifying them – and evaluating them on response gap and benefit-risk together – is the work this clinical question turns on.¹

Consider non-oral options (injectable, nasal spray, devices) when nausea, vomiting, or gastroparesis is present. There may be different migraine profiles that require a different acute treatment plan.⁹